This content is not available in your region

Takeda proposes sale of Shire drug to gain European approval

Access to the comments Comments
Takeda proposes sale of Shire drug to gain European approval
FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon - RC1702FA7D40/File Photo   -   Copyright  Kim Kyung Hoon(Reuters)
Text size Aa Aa

(Reuters) – Takeda Pharmaceutical Co Ltd <4502.T> has proposed to European regulators it could sell a Shire <SHP.L> treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies’ merger.

The Japanese drug developer said it had proposed divesting Shire’s pipeline compound SHP647, which is currently in Phase III clinical trials, along with some associated rights.

It said it did not expect the issue to delay its closing of the takeover of Shire and was the only issue it was discussing with European Union regulators after receiving approvals in China and Japan for the deal.

(Reporting by Arathy S Nair in Bengaluru)

Euronews provides articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.